Phylo and Chugai Deploy AI Platform to Accelerate Drug Discovery

Phylo partners with Japanese drug maker Chugai to launch an artificial‑intelligence platform aimed at drug discovery. The agreement will combine Phylo’s computational tools with Chugai’s research pipelines. The partnership will involve joint development and testing of the platform.

Chugai expects the AI system to streamline early‑stage screening, reducing time needed to evaluate chemical compounds. Company officials said the collaboration will focus on integrating the platform into existing laboratory workflows. Chugai plans to integrate AI output into its lead optimization workflow.

AI platform will be deployed across Chugai’s research sites, targeting diseases where new treatments are needed. The joint effort reflects a growing trend of pharma firms adopting machine‑learning methods to enhance discovery efficiency.

Industry observers note that the Phylo‑Chugai alliance illustrates increasing reliance on artificial intelligence to accelerate pharmaceutical research, potentially influencing investment patterns in biotech AI solutions.